Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2025-08-27 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Data published -European Journal of Heart Failure
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces positive clinical trial results for the company's product, ACCRUFeR/FeRACCRU, published in a medical journal. As it is a general regulatory announcement regarding company news that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2025-08-27 English
Interim results for the six months ended 30 Jun 25
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim results' announcement for the six months ended 30 June 2025. It contains detailed financial highlights (Group revenues, loss, cash position) and operational highlights. While it is an announcement, it provides substantive financial data and analysis for the interim period, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-21 English
Q2 2025 Trading Update
Earnings Release Classification · 100% confidence The document is a 'Q2 2025 Trading Update' issued by Shield Therapeutics plc. It provides key financial metrics (net revenues, cash position, and average selling price) for the second quarter of 2025. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly/periodical financial results, which matches the content and purpose of this document. It is not a full report (10-K or IR) nor a mere announcement of a report (RPA), as it contains the actual financial data and management commentary. Q2 2025
2025-07-23 English
Group of companies' accounts made up to 2024-12-31
Regulatory Filings
2025-06-06 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from Shield Therapeutics plc regarding the 'Results of 2025 Annual General Meeting'. It provides a detailed table of voting results for various resolutions (ordinary and special) passed during the meeting. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-05-22 English
Shield Therapeutics plc 2024 Annual Report and Accounts
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2024' and contains comprehensive sections including a strategic report, corporate governance, financial statements, and an independent auditor's report. It provides detailed financial performance, business strategy, and operational highlights for the fiscal year 2024, fitting the definition of an Annual Report (10-K). FY 2024
2025-05-22 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.